Merck Unveils PD-1xVEGF Data, Delays Phase 3 Plans | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and regulatory updates that are shaping the future of the industry. At the latest meeting of the American Association for Cancer Research, innovative cancer therapies were in the spotlight. Merck showcased its PD-1xVEGF bispecific antibody for non-small cell lung cancer, combining immune checkpoint inhib...
AI Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Pharma and BioTech Daily
Novartis' $23B U.S. Investment Boosts Pharma Manufacturing | Pharma and Biotech Daily
AstraZeneca's £300M UK Investment Resumes Amid FDA Pilot | Pharma and Biotech Daily
AstraZeneca's Breztri Asthma Approval Boosts $80B Goal | Pharma and Biotech Daily
Sun Pharma's $11.75B Organon Deal: Industry Shockwave | Pharma and Biotech Daily
Get summaries like this every morning.
Free AI-powered recaps of Pharma and BioTech Daily and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.